Clinical Trial Update: AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating azacitidine plus venetoclax as maintenance therapy in patients with acute myeloid leukemia in remission, including FLT3-mutate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING